Testing (18F)-FEPPA for frontotemporal dementia

Exclusion

• −Any significant neurologic disease other than suspected Frontotemporal Dementia that would better account for symptoms (i.e. frontal lobe stroke).
• −ScreeningScreeningThe checks done before joining, to see whether a study fits.Read more →/baselineBaselineYour starting measurements, taken before treatment begins.Read more → MRI scans with evidence of infection, infarction, or other focal lesions. Subjects with multiple lacunes are excluded.
• −Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body that may preclude MRI participation as per MRI screening form.
• −Major depression, bipolar disorder as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocolProtocolThe detailed plan a study must follow.Read more →.
• −History of schizophrenia (DSM IV criteria).
• −Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
• −Clinically significant abnormalities in B12, or thyroid function tests that might interfere with the study.
• −Investigational agents are prohibited one month prior to entry and for the duration of the trial.
• −ExclusionExclusion criteriaThe things that would prevent someone from taking part.Read more → for FEPPA: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed the limits of annual and total dose commitment set forth. The current regulation for radiation dose to patient volunteers and health controlControl groupThe group a new treatment is measured against.Read more → volunteers are contained within Health Canada's recently amended (June 19, 2012) Regulations Amending the Food and Drug Regulations (Positron-emitting Radiopharmaceuticals). Limitations for effective total body dose is 50 mSv (C.03.305 (c)) which has been increased from the previous values of 20 mSv (Table 1 in INFO-0491).
• −Exclusion Criteria for controls undergoing arterial line placement: Absent pulse, Thromboangiitis obliterans (Buerger disease), Burns over the cannulation siteTrial siteA hospital or clinic where a study is actually run.Read more →, Inadequate circulation to the extremity, Raynaud syndrome, Anticoagulation therapy, Atherosclerosis of upper extremity vessels, Coagulopathy, inadequate collateral flow, Infection at the cannulation site, Previous surgery in the area, Synthetic vascular graft.